Anesthesiologists, Pain Management Specialist
22 years of experience
Video profile
Accepting new patients
Harlow
Pain Consultants Of Oregon
360 S Garden Way
Ste 101
Eugene, OR 97401
541-684-9451
Locations and availability (1)

Education ?

Medical School Score Rankings
University of California at Los Angeles (1988)
  • Currently 4 of 4 apples
Top 25%

Awards & Distinctions ?

Awards  
? Outstanding Anesthesia Faculty, Stanford 1992-1993
? Outstanding Anesthesia Resident, Stanford 1991-1992
Outstanding Anesthesia Resident, Stanford 1991-1992
Outstanding Anesthesia Faculty, Stanford 1992-1993
‘Class Act’ teaching award, Oregon Health Sciences University 1994-1995
Associations
American Board of Anesthesiology
American Academy of Pain Medicine

Affiliations ?

Dr. Kosek is affiliated with 10 hospitals.

Hospital Affilations

Score

Rankings

  • Cottage Grove Hospital
    1515 Village Dr, Cottage Grove, OR 97424
    • Currently 4 of 4 crosses
    Top 25%
  • Sacred Heart Medical Center
    1255 Hilyard St, Eugene, OR 97401
    • Currently 4 of 4 crosses
    Top 25%
  • Peace Harbor Hospital
    400 9th St, Florence, OR 97439
    • Currently 3 of 4 crosses
    Top 50%
  • McKenzie - Willamette Medical Center
    1460 G St, Springfield, OR 97477
    • Currently 2 of 4 crosses
  • St John's Medical Center
  • Sacred Heart Medical Center - Riverbend 9/2/1998 Active Current Pain Management
  • Sacred Heart Medical Center At Riverbend
    3333 Riverbend Dr, Springfield, OR 97477
  • Sacred Heart Medical Center - University Dist 9/2/1998 Courtesy Current Pain Management
  • St. Joseph's Hospital
  • Sacred Heart-University Distr
  • Publications & Research

    Dr. Kosek has contributed to 3 publications.
    Title Phase Ii, Open-label, Multicenter Study of Combined Intrathecal Morphine and Ziconotide: Addition of Ziconotide in Patients Receiving Intrathecal Morphine for Severe Chronic Pain.
    Date June 2008
    Journal Pain Medicine (malden, Mass.)
    Excerpt

    OBJECTIVE: To assess the safety and efficacy of adding intrathecal ziconotide to intrathecal morphine in patients being treated with a stable intrathecal morphine dose. DESIGN: Phase II, multicenter, open-label study with a 5-week titration phase and an extension phase. SETTING: Outpatient clinics. PATIENTS: Patients with suboptimal pain relief receiving stable intrathecal morphine doses (2-20 mg/day). INTERVENTIONS: Intrathecal morphine dosing remained constant during the titration phase. Ziconotide therapy began at 0.60 microg/day and was titrated to a maximum of 7.2 microg/day. During the extension phase, ziconotide and intrathecal morphine dosing were adjusted at the investigator's discretion. OUTCOME MEASURES: Safety was assessed primarily via adverse event reports. Efficacy was analyzed via percentage change on the visual analog scale of pain intensity and in weekly systemic opioid consumption. RESULTS: Twenty-six patients were enrolled. Treatment-emergent adverse events were generally mild or moderate; the most common (> or = 15% of patients in either study phase) study drug-related (i.e., ziconotide/morphine combination [or ziconotide monotherapy in the extension phase only]) events were confusion, dizziness, abnormal gait, hallucinations, and anxiety. The mean percentage improvement in visual analog scale of pain intensity scores was 14.5% (95% confidence interval: -9.4% to 38.5%) from baseline to week 5 and varied during the extension phase (range: -0.4% to 42.8%). Mean percentage change from baseline in systemic opioid consumption was -14.3% at week 5 and varied considerably during the extension phase. CONCLUSIONS: Ziconotide, combined with stable intrathecal morphine, may reduce pain and decrease systemic opioid use in patients with pain inadequately controlled by intrathecal morphine alone.

    Title The Effect of Cimetidine and Ranitidine on the Duration of Action of Succinylcholine.
    Date March 1989
    Journal Anesthesia and Analgesia
    Excerpt

    A recent study suggested that cimetidine prolongs the duration of action of succinylcholine (SCh). We examined this reported interaction, and investigated whether it is the result of inhibition of plasma cholinesterase (PChE). We also studied the effect of ranitidine on the duration of action of succinylcholine. Thirty patients were randomly assigned to three groups to receive oral cimetidine 300 mg or ranitidine 150 mg or no H2-antagonist the night before surgery and again 1-2 hours prior to induction of anesthesia. Succinylcholine (1.5 mg/kg i.v.) was given to facilitate tracheal intubation after induction of anesthesia; neuromuscular function was monitored by evoked compound electromyogram. Pretreatment blood samples were analyzed for PChE activity. PChE activity and levels of appropriate H2-antagonists were measured in preinduction blood samples. No significant effect of either cimetidine or ranitidine on the duration of action of SCh or PChE activity was demonstrated. We conclude that H2-antagonists administered preoperatively do not prolong the duration of action of succinylcholine or alter PChE activity.

    Title Minimizing Movement-induced Changes in Twitch Response During Integrated Electromyography.
    Date August 1988
    Journal Anesthesiology

    Similar doctors nearby

    Dr. Brian Starr

    Anesthesiology
    5 years experience
    Eugene, OR

    Dr. Donna Morgan

    Anesthesiology
    18 years experience
    Eugene, OR

    Dr. Joseph Dunn

    Anesthesiology
    22 years experience
    Eugene, OR

    Dr. Laura Hartman

    Anesthesiology
    23 years experience
    Springfield, OR

    Dr. Judith Ekstrom

    Anesthesiology
    27 years experience
    Eugene, OR

    Dr. Isaac Yuan

    Anesthesiology
    30 years experience
    Eugene, OR
    Search All Similar Doctors